Terumo to acquire OrganOx in ~$1.5B deal, entering organ-transplant technology

TOKYO — Aug. 25, 2025. Terumo (TSE: 4543) has signed a definitive agreement to acquire UK-based OrganOx, a pioneer in normothermic machine perfusion (NMP) for organ preservation, in a transaction valued at approximately USD 1.5 billion. The deal follows a March investment by Terumo Ventures and positions the company for long-term growth in transplantation technology, subject to regulatory approvals.

OrganOx’s FDA-cleared metra liver NMP device—also approved in the EU, UK, Australia and Canada—has supported 6,000+ liver transplants globally since launch, with a kidney NMP platform in development. Terumo plans to scale OrganOx’s platform, citing potential to improve organ utilization (including “marginal” donors), outcomes and care-team workflow by reducing emergency procedures.

“Organ transplantation is a last resort for many patients, and donated organs are a precious resource,” said Terumo CEO Hikaru Samejima. “With OrganOx, we aim to deliver solutions that address key challenges in transplantation.”

Executive perspective: Ørn R. Stuge, MD, MBA—Executive Chairman of OrganOx—said the transaction should accelerate adoption by leveraging Terumo’s global infrastructure. Stuge is also the Founder/Chairman of Orsco Lifesciences AG and an experienced medtech board leader. (Orsco Life Sciences, OrganOx)

Closing is expected promptly after U.S. regulatory clearances; final consideration will be adjusted for cash, debt and working capital; Terumo intends to finance via borrowings. 

PressRelease_20250825_E.pdf

Download PDF • 191KB